Illumina Inc. (ILMN:NASDAQ)

Illumina Inc. announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89. Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, plus individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. The Genome Analyzer offers the highest rate of daily output and the simplest and most user-friendly workflow. The Genome Analyzer also offers the broadest set of supported applications, including whole transcriptome profiling and discovery, epigenetic studies, whole genome resequencing, de novo sequencing, targeted resequencing, ChIP-sequencing bi-sulfite sequencing (DNA methylation), small RNA, mRNA, tag profiling and metagenomics.

Illumina Inc. reported earnings results for the third quarter and nine months ended September 27, 2009. For the third quarter of 2009, Illumina reported revenue of $158.4 million, a 5% increase over the $150.3 million reported in the third quarter of 2008. The Company reported net income for the quarter of $17.1 million, or $0.12 per diluted share, compared to net loss of $10.1 million, or $0.08 per diluted share in the comparable period of 2008. The net loss in the prior year period was directly attributable to a $24.7 million in process research and development charge associated with the Company's acquisition of Avantome Inc. Net income for the third quarter of 2009 included non-cash charges of $14.6 million in stock compensation expense, $4.8 million in non-cash interest expense, and other items listed in the table entitled 'An itemized Reconciliation Between GAAP and Non-GAAP Net Income (Loss).' Excluding the impact of these items, and net of pro forma tax expense, Illumina's net income on a non-GAAP basis for the third quarter of 2009 was $32.3 million, or $0.24 per diluted share, compared to $28.6 million, or $0.22 per diluted share, for the third quarter of 2008. The Company generated $23.1 million in cash flow from operations during the third quarter of 2009 compared to $27.3 million in the prior year period. The company reported income from operations of $29.299 million and income before income taxes of $27.463 million compared to the income from operations of $1.536 million and loss before income taxes of $614,000 for the same period a year ago. The company announced purchase of property and equipment of $19.697 million compared to the purchase of property and equipment of $15.316 million for the same period a year ago. For nine months, the company reported net income of $60.576 million or $0.44 per diluted shrew on total revenue of $485.760 million compared to the net income of $13.324 million or $0.10 per diluted shrew on total revenue of $412.298 million for the same period a year ago. The company reported income from operations of $99.910 million and income before income taxes of $91.837 million compared to the income from operations of $44.381 million and income before income taxes of $37.707 million for the same period a year ago. The company reported that net cash provided by operating activities of $113.168 million compared to the net cash provided by operating activities of $37.765 million for the same period a year ago. The company announced purchase of property and equipment of $46.288 million compared to the purchase of property and equipment of $45.139 million for the same period a year ago. The company reported non-GAAP net income of $107.107 million or $0.82 per diluted share compared to the non-GAAP net income of $78.574 million or $0.63 per diluted share for the same period a year ago. For the fourth quarter of 2009, the company expect minimum revenues of $165 million which implies full-year 2009 revenues of $651 million. This represents year-over-year growth of 3% in the fourth quarter and 14% for the full year. The company expect non-GAAP earnings per fully diluted pro forma share in the fourth quarter between $0.24 and $0.25 and $1.05 to $1.06 for the full-year. The company believe total capital expenditures will be approximately $52 million for 2009.

Illumina Inc. announced the launch and immediate availability of cBot, a new standard for ease-of-use and sequencing workflow automation. cBot is a revolutionary plug-and-play, user installable system for clonal amplification of sequencing libraries. Its automated design eliminates user intervention and enables clonal amplification to be performed in four hours with less than ten minutes of hands-on time. cBot innovations include ready-to-use, pre-packaged reagents, simple touch-screen operation, and browser-based remote monitoring. High quality results are assured by smart sensors that monitor instrument performance, combined with new chemistry and protocols that deliver higher density clusters and improved sequencing accuracy. Illumina's proprietary cluster generation process offers major advantages over competing emulsion PCR-based methods in terms of simplicity and hands-on time. cBot now widens that gap by minimizing user touch points, improving chemistry for higher quality results, and decreasing hands-on time to less than ten minutes.